Ahmed Bouzidi, presented at the iProve workshop for therapeutic vaccines and SMEs organized by Vaccines Europe
Created in 2009, Vaxeal Holding SA is an SME headquartered in Vevey (Switzerland). The company, in partnership with leading International Research Institutes, is developing therapeutic vaccines in combination with immuno-modulatory drugs for the treatment of cancers and infectious diseases. The cutting-edge immunotherapies are protected by several patent families. Our initial programs have reached the pre-clinical stage in major disease segments, and are expected to enter into clinical trials in Europe in 2016. Vaxeal is member of Vaccines Europe, and the European Biopharmaceutical Enterprises. The company received a special MIT award for “its remarkable breakthrough in the field of vaccines”.About Vaccines EuropeVaccines Europe is a specialised vaccines group within the European Federation of Pharmaceutical Industries and Associations (EFPIA), the professional association of the pharmaceutical industry in Europe. Formed in 1991, Vaccines Europe represents innovative research-based global vaccine companies operating in Europe. Companies represented within Vaccines Europe are involved in research and development (R&D), clinical trials, production and marketing of vaccines and are dedicated to improving public health through immunisation. The Vaccines Europe members are: Abbott Biologicals, AstraZeneca, BioCSL, Crucell, GlaxoSmithKline Vaccines, ImmBio, MSD, Novartis Vaccines, Pfizer Vaccines, Sanofi Pasteur, Sanofi Pasteur MSD, Takeda, and Vaxeal. More information on Vaccines Europe is available at www.vaccineseurope.eu.
- Posted by Elliot Willcox
- On 26 May 2015
- 0 Comments